Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43824
UPID:
GTPB6_HUMAN
Alternative names:
Pseudoautosomal GTP-binding protein-like
Alternative UPACC:
O43824; H0Y2S1; Q53F77; Q5HYX8
Background:
Putative GTP-binding protein 6, also known as Pseudoautosomal GTP-binding protein-like, represents a unique class of proteins with potential GTPase activity. Despite its elusive role in cellular processes, its classification suggests involvement in molecular signaling pathways that are critical for cellular function and communication.
Therapeutic significance:
Understanding the role of Putative GTP-binding protein 6 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways makes it a promising target for drug discovery, aiming to modulate its activity for therapeutic benefits.